Nidhi Subbaraman writes for BetaBoston about MIT’s Atlas robot ahead of its participation in an international competition hosted by the Defense Advanced Research Projects Agency (DARPA). “This is the most advanced, sophisticated machine I’ve ever worked on,” said team lead Professor Russ Tedrake.
Philips is moving its North American research headquarters to Kendall Square and has announced a $25 million research alliance with MIT, reports Boston Globe correspondent Karen Weintraub. MIT and Philips have a “resonance on specific technical issues, but also on the approach to innovation,” says Associate Provost Karen Gleason.
Gus Iverson writes for DOTmed about the new alliance between MIT and Philips aimed at spurring innovation in health care and lighting solutions technology. Philips will also be relocating its research hub to Kendall Square, which Henk van Houten, executive vice president and general manager of Philips Research, called "a thriving innovation ecosystem."
In a post for BetaBoston, Senior Lecturer Steven Spear urges the Boston 2024 committee to use videos and other representations to demonstrate what it would be like to host the Olympics: “Such simulations could help give people a sense of what something that occurs on the scale of the Games will look and feel like in practice.”
MIT celebrated the induction of Robert Robinson Taylor, the Institute’s first African American graduate, into the U.S. Postal Service’s Black Heritage Stamp series. “Robert Robinson Taylor graduated MIT in 1892 and is believed to be the country’s first academically trained black architect,” reports Sara Feijo for The Cambridge Chronicle.
Jonathan Amos reports for The BBC on new advanced laser interferometer gravitational observatory (LIGO) facilities that are part of a project headed by MIT and Caltech to detect gravitational waves resulting from extreme cosmic events: “Confirmation of the waves' existence should open up a new paradigm in astronomy,” writes Amos.
According to The Boston Herald, “Amsterdam’s Royal Philips N.V and the Massachusetts Institute of Technology have signed a five-year, $25 million research alliance to develop healthtech solutions and digital connected lighting systems.” Philips will also move its North American research headquarters to Cambridge.
ChemE graduate student Carl Schoellhammer has won the $15,000 Lemelson-MIT National Collegiate Student Prize for his Microneedle Pill, which can deliver injectable medications without a syringe. As Sarah Hedgecock at Forbes notes, “The stainless-steel, needle-spiked capsule is filled with the desired medication in the needed dose.”
MedTech Boston reporter Jenni Whalen writes that Philips has formed an alliance with MIT and plans to move its North American research headquarters to Cambridge. “By moving to Cambridge and collaborating with MIT, its staff and its partners, Philips can work with some of the best minds in the world,” explains Henk van Houten, executive vice president and general manager of Philips Research.
Stacey Higginbotham of Fortune writes about a new $25 million partnership between Philips and MIT in which the company will move its North American R&D headquarters to Cambridge: “Given that Philips will focus on lighting and healthcare technology for its R&D, Boston makes a considerable amount of sense, especially on the health side.”
Elisabeth Reynolds, Executive Director of MIT’s Industrial Performance Center (IPC), speaks with Bob Seay of WGBH about a new IPC report that recommends greater interconnectedness in Massachusetts’ manufacturing innovation ecosystem. “What we know is that there is a very vital link between our manufacturing and innovation capabilities,” says Reynolds.
After the release of a paper from U.C. Berkeley researchers detailing how certain strains of yeast may be used to produce opioids, Professor Kenneth Oye coauthored a commentary calling for regulation in the field, writes Lexi Pandell for Wired. “I haven’t seen anything quite like this before,” says Oye.
Rachel Feltman writes for The Washington Post about a commentary by Professor Kenneth Oye that calls for regulation of genetically modified yeast that could potentially produce opiates. “It’s not like tomorrow someone’s going to have a fully integrated, one-pot pathway to go from sugar to morphine,” says Oye. “But it’s coming.”
Michael Le Page writes for The New Scientist about Professor Kenneth Oye’s commentary on research indicating that genetically engineered yeasts could be used to produce opiates. Oye provides a number of policy recommendations to prevent illicit opium production, including outlawing the distribution of opiate-making yeast strains.
Professor Kenneth Oye has coauthored a commentary on a paper that demonstrates researchers may be close to being able to engineer morphine from yeast, writes Nicola Twilley for The New Yorker. The authors worry this “could put illicit opiate production into the hands of many more people, at a much smaller scale.”